Logo image of ORPH

ORPHAZYME A/S - ADR (ORPH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ORPH - ADR

0.87
-0.02 (-2.25%)
Last: 3/30/2022, 9:50:21 PM
0.8002
-0.07 (-8.02%)
After Hours: 3/30/2022, 9:50:21 PM
Fundamental Rating

1

ORPH gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. ORPH has a bad profitability rating. Also its financial health evaluation is rather negative. ORPH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ORPH has reported negative net income.
ORPH Yearly Net Income VS EBIT VS OCF VS FCFORPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -200M -400M -600M

1.2 Ratios

Industry RankSector Rank
ROA -197.56%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ORPH Yearly ROA, ROE, ROICORPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 -200 -400 -600

1.3 Margins

The Operating Margin and Gross Margin are not available for ORPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -6429.52%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORPH Yearly Profit, Operating, Gross MarginsORPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for ORPH has been increased compared to 1 year ago.
The debt/assets ratio for ORPH has been reduced compared to a year ago.
ORPH Yearly Shares OutstandingORPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 10M 20M 30M
ORPH Yearly Total Debt VS Total AssetsORPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 200M 400M 600M 800M

2.2 Solvency

ORPH has an Altman-Z score of -11.76. This is a bad value and indicates that ORPH is not financially healthy and even has some risk of bankruptcy.
ORPH has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -11.76
ROIC/WACCN/A
WACCN/A
ORPH Yearly LT Debt VS Equity VS FCFORPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 200M -200M 400M -400M 600M

2.3 Liquidity

ORPH has a Current Ratio of 1.80. This is a normal value and indicates that ORPH is financially healthy and should not expect problems in meeting its short term obligations.
ORPH has a Quick Ratio of 1.80. This is a normal value and indicates that ORPH is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.8
Quick Ratio 1.8
ORPH Yearly Current Assets VS Current LiabilitesORPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

ORPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.51%.
EPS 1Y (TTM)-37.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.64% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.09%
EPS Next 2Y-9.63%
EPS Next 3Y-6.47%
EPS Next 5Y5.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORPH Yearly Revenue VS EstimatesORPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 50M 100M 150M 200M
ORPH Yearly EPS VS EstimatesORPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ORPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORPH Price Earnings VS Forward Price EarningsORPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.09
ORPH Per share dataORPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as ORPH's earnings are expected to decrease with -6.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.63%
EPS Next 3Y-6.47%

More info and screens

0

5. Dividend

5.1 Amount

ORPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORPHAZYME A/S - ADR

NASDAQ:ORPH (3/30/2022, 9:50:21 PM)

After market: 0.8002 -0.07 (-8.02%)

0.87

-0.02 (-2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04 2022-03-04/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap30.72M
Revenue(TTM)13.15M
Net Income(TTM)-845.61M
Analysts37.78
Price Target15.81 (1717.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.72
P/FCF N/A
P/OCF N/A
P/B 1.24
P/tB N/A
EV/EBITDA 0.09
EPS(TTM)-3.79
EYN/A
EPS(NY)-3.33
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.06
BVpS0.7
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -197.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -6429.52%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.8
Quick Ratio 1.8
Altman-Z -11.76
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34.49%
EPS Next Y18.09%
EPS Next 2Y-9.63%
EPS Next 3Y-6.47%
EPS Next 5Y5.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ORPHAZYME A/S - ADR / ORPH FAQ

Can you provide the ChartMill fundamental rating for ORPHAZYME A/S - ADR?

ChartMill assigns a fundamental rating of 1 / 10 to ORPH.


What is the valuation status of ORPHAZYME A/S - ADR (ORPH) stock?

ChartMill assigns a valuation rating of 3 / 10 to ORPHAZYME A/S - ADR (ORPH). This can be considered as Overvalued.


Can you provide the profitability details for ORPHAZYME A/S - ADR?

ORPHAZYME A/S - ADR (ORPH) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ORPHAZYME A/S - ADR?

The Earnings per Share (EPS) of ORPHAZYME A/S - ADR (ORPH) is expected to grow by 18.09% in the next year.